Biologic indicators of prognosis in breast cancer.
With increasing options for adjuvant therapy in breast cancer, it is even more important to know which patients are at risk for recurrent disease. Variables such as tumor size and node status are well-established markers. Others have recently been proposed. Will these new markers improve our ability to assess prognosis and select appropriate management modalities?
Robert
N J
NJ
New England Medical Center, Boston.
D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics; D002402:Cathepsin D / Q000032:analysis; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008207:Lymphatic Metastasis; D008327:Mammography; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000453:epidemiology / Q000235:genetics; D009857:Oncogenes; D011379:Prognosis; D011519:Proto-Oncogenes; D012307:Risk Factors
D014408:Biomarkers, Tumor; D066246:ErbB Receptors; D002402:Cathepsin D